Equities research analysts expect that Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) will announce sales of $250,000.00 for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Crinetics Pharmaceuticals’ earnings, with estimates ranging from $100,000.00 to $550,000.00. The firm is expected to report its next quarterly earnings results on Wednesday, June 12th.

On average, analysts expect that Crinetics Pharmaceuticals will report full year sales of $1.04 million for the current fiscal year, with estimates ranging from $420,000.00 to $2.20 million. For the next fiscal year, analysts anticipate that the business will post sales of $0.00. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings data on Wednesday, March 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.06. The company had revenue of $0.78 million for the quarter, compared to analysts’ expectations of $0.32 million. Crinetics Pharmaceuticals had a negative net margin of 1,117.52% and a negative return on equity of 38.38%.

Several equities analysts have issued reports on CRNX shares. HC Wainwright reissued a “buy” rating on shares of Crinetics Pharmaceuticals in a research note on Tuesday, April 16th. Cantor Fitzgerald started coverage on shares of Crinetics Pharmaceuticals in a research note on Monday, March 11th. They issued an “overweight” rating and a $40.00 price objective on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $37.20.

In other Crinetics Pharmaceuticals news, major shareholder Ventures Iv L.P. 5Am sold 154,839 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $24.25, for a total value of $3,754,845.75. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Vivo Capital Fund Viii, L.P. sold 417,000 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $22.25, for a total transaction of $9,278,250.00. The disclosure for this sale can be found here.

Large investors have recently bought and sold shares of the company. Rhumbline Advisers acquired a new position in shares of Crinetics Pharmaceuticals during the 4th quarter worth $254,000. TIAA CREF Investment Management LLC acquired a new position in shares of Crinetics Pharmaceuticals during the 3rd quarter worth $268,000. Vanguard Group Inc. acquired a new position in shares of Crinetics Pharmaceuticals during the 3rd quarter worth $7,103,000. Bank of New York Mellon Corp acquired a new position in shares of Crinetics Pharmaceuticals during the 3rd quarter worth $453,000. Finally, Emory University acquired a new position in shares of Crinetics Pharmaceuticals during the 4th quarter worth $2,577,000. 69.18% of the stock is currently owned by institutional investors and hedge funds.

Shares of CRNX opened at $25.07 on Tuesday. The firm has a market capitalization of $626.28 million and a price-to-earnings ratio of -11.24. Crinetics Pharmaceuticals has a 1 year low of $19.23 and a 1 year high of $42.00.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.

Featured Story: Why Invest in Dividend Achievers?

Get a free copy of the Zacks research report on Crinetics Pharmaceuticals (CRNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.